# Flibanserin Evaluation Over 28 Additional Weeks in Hypoactive Sexual Desire Disorder

> **NCT00601367** · PHASE3 · COMPLETED · sponsor: **Sprout Pharmaceuticals, Inc** · enrollment: 480 (actual)

## Conditions studied

- Sexual Dysfunctions, Psychological

## Interventions

- **DRUG:** flibanserin flexible dose

## Key facts

- **NCT ID:** NCT00601367
- **Lead sponsor:** Sprout Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2009-10
- **Final completion:** 2009-10
- **Target enrollment:** 480 (ACTUAL)
- **Last updated:** 2014-06-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00601367

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00601367, "Flibanserin Evaluation Over 28 Additional Weeks in Hypoactive Sexual Desire Disorder". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00601367. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*